Comparative Pharmacology
Head-to-head clinical analysis: ISOETHARINE HYDROCHLORIDE versus METAPROTERENOL SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOETHARINE HYDROCHLORIDE versus METAPROTERENOL SULFATE.
ISOETHARINE HYDROCHLORIDE vs METAPROTERENOL SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ISOETHARINE HYDROCHLORIDE is a beta-2 adrenergic receptor agonist that stimulates adenylate cyclase, increasing cyclic AMP (cAMP) in bronchial smooth muscle, leading to bronchodilation. It also has beta-1 activity at higher doses, causing cardiac stimulation.
Selective beta-2 adrenergic receptor agonist that activates adenylate cyclase, increasing intracellular cyclic AMP leading to bronchodilation and inhibition of mast cell mediator release.
Inhalation via nebulizer: 0.5 mL (2.5 mg) of 0.5% solution diluted in 2-3 mL normal saline, administered over 10-20 minutes, every 4-6 hours as needed.
2.5 mg (0.25 mL of 1% solution) by nebulization every 6-8 hours. For oral, 20 mg every 6-8 hours.
None Documented
None Documented
1.6 to 2.7 hours in adults; may be prolonged in patients with hepatic or renal impairment.
Terminal elimination half-life: 2-6 hours. Clinical context: Shorter half-life requires frequent dosing; prolongation in renal impairment.
Primarily renal excretion of unchanged drug and metabolites; approximately 60-80% of a dose is excreted in urine within 24 hours, with the remainder excreted in feces via biliary elimination.
Renal: 40-60% as unchanged drug and metabolites; biliary/fecal: ~40% as metabolites.
Category C
Category C
Beta-2 Adrenergic Agonist
Beta-2 Adrenergic Agonist